Dr. Perrine has founded 3 biotech companies and has strategic and operational experience from first- in-man to Ph3 in hematology and oncology conditions.
Prior roles include CSO, Gene Regulation Laboratories, CSO/VP Clinical, HemaQuest, and Professor of Medicine, Pediatrics, Pharmacology and Experimental Therapeutics, Boston University School of Medicine. Education at Harvard School of Public Health, Tufts University School of Medicine and Tufts Medical Center, Children's Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School.
Douglas V. Faller MD, PhD
Chief Science Officer
Dr. Faller is inventor of the virology and oncology technology platforms, novel approaches to disrupting uncontrolled growth of multiple cancer types. He leads multiple global clinical programs in pharma and served as Director of the Cancer Center at Boston University School of Medicine. Education at Harvard Medical School, MIT, University of California San Francisco, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Boston Children's Hospital
Strategic Advisors
Advisors
Company advisors are distinguished experts in hematology-oncology conditions, Regulatory Strategy, Business Development and Commercialization, Drug Development and repurposing.
